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Objectives To determine, for the last 5 years in children onMerseysidewith clinical meningococcal
disease (MCD), the impact on diagnostic yield of newer bacteriologic methods; bacterial antigen detection
(AD) and polymerase chain reaction (PCR).
Methods Prospective data collection at Royal Liverpool Children's Hospital over two epochs: 1September
1992 to 30 April 1994 (epoch A, n126) and17November1997 to15 September1998 (epoch B, n 85).
Results Epoch Awas comparedwith epoch B. Diagnosis was con¢rmed bydetection of meningococci in
78 of126 (61.9%) versus 64 of 85 (75.3%, P 0.04), but with a signi¢cantly lower rate of positive blood and
cerebrospinal £uid culture in the later epoch.The proportion of cases receiving penicillin pretreatment was
unchanged at 32%, but the proportion undergoing lumbar puncture decreased signi¢cantly.Median ages
were higher in epoch B: 1.7 years versus 2.49 years (P 0.013,Mann^Whitney).Therewas a signi¢cant
increase in the proportion of cases due to serogroupC (14/78 (18%) versus 30/64 (46.9%), P 0.001).
Conclusions Culture detection of meningococci from childrenwithMCDhas reduced, as less lumbar
punctures are done. However, improved diagnosis by PCRandADhas increasedmicrobiological
con¢rmation overall. SerogroupC disease and themedian age of cases continue to rise.
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I N T R O D U C T I O N
Meningococcal disease (MCD) is a major cause of morbidity
and mortality. Most reported series of childrenwith MCD are
based on cohorts with clinically diagnosed MCD, with some
casescon¢rmedbyappropriatemicrobiological investigations.
However, over the wide spectrum of disease, bacterial
detection is possible in only 70^80% of cases.The diagnosis of
MCD is con¢rmed on blood culture in only 40^60% of cases,
and less if prior antibiotics have been administered [1]. Menin-
gococcal antigens can be detected in the cerebrospinal £uid
(CSF) or blood in about 60% of culture-negative patients [2].
CSF is culture positive in 80% of cases with meningitis, but
usually negative in children with septicemia [3]. Needle aspi-
rates from skin lesions may yield positive results in 63% of
cases, on culture, Gram stain, or both [4].
Increasing the diagnostic yield is desirable both to facilitate
clinical and outbreak case management (whichmay rest on the
clinician's suspicion of MCD, but can result in considerable
deploymentof resources) and tovalidate researchdata.Oneway
ofincreasingdiagnosticyieldistousebacterialantigendetection
tests (AD) and polymerase chain reaction ampli¢cation of
meningococcalDNA(PCR).Thesearenotyetusedinallcases.
The proportion of cases of MCD caused by strains of ser-
ogroup C is increasing [5]. Clusters caused mainly by ser-
ogroup C strains have increased considerably, particularly
among students at schools and universities. Current priorities
are to optimize recognition, diagnosis and management [6].
With the introduction of the conjugate group C meningococ-
cal vaccine to the UK, it is now even more important to con-
¢rm the diagnosis of MCD and the causative serogroup.This
e`nhanced surveillance' is recommended, but not often per-
formed [7].
Merseyside is a region of England with a high incidence of
MCD; in 1998 the incidence on Merseyside was 7.0/100 000
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per year, compared to 5.1/100 000 per year in England and
Wales as a whole. MCD therefore represents a signi¢cant bur-
den of disease in this region. This study aimed to determine
whether the rate of microbiological con¢rmation could be
increased, particularly in viewof the increase in penicillin pre-
treatment by general practitioners, which may decrease the
proportion of culture-positive cases. Such data will provide
information for clinicians treating MCD and consultants in
communicable disease control during cluster and outbreak
management. It may also help to determine vaccine e¤cacy.
M E T H O D S
Eighty-¢ve children admitted to RLCH, with a clinical diag-
nosis of probable MCD, were prospectively studied between
mid-November 1997 and mid-September 1998. A probable
case was de¢ned as a feverish, ill patient with a petechial/pur-
puric rash without microbiological con¢rmation [8]. Parental
consent was obtained before inclusion into the study. The
Local Research Ethics Committee approved the study.
All children had blood cultures and full blood counts. In
addition, 81 had blood or CSF meningococcal antigen tests,
and 79 had meningococcal PCRof blood or CSF. Data collec-
tion included demographic information, history and exami-
nation ¢ndings, and laboratory results. These were compared
with similarly de¢ned, prospectively collected data for the
time period September1992 toApril 1994 (126 children) [9].
Antigen detection tests were done using a latex agglutina-
tion method (Wellcogen Bacterial Antigen test kit). PCRwas
performed at the PHLS Meningococcal Reference Unit
(MRU) in Manchester, UK, using an automated PCR sys-
temöTaqman (PE-ABI, Warrington, UK). The MRU uses
three PCR tests; two screening assays based on the IS1106
sequence [10] and the ctrA gene, and a third PCR assay used on
specimens reactive in either or both screening tests, based on
the sialyltransferase gene sequence, which is able to discrimi-
nate between serogroups B and C. The assays have been
adapted to a PCR enzyme-linked immunosorbent assay for-
mat using the Boehringer Mannheim digoxigen labeling sys-
tem followed by an ELISA-based detection using biotin-
labeled sequence-speci¢c probes [11].
Statistical analysis was performed using Statistical Package
for Social Sciences (SPSS) software on a Pentium II PC. Med-
ian ages were compared using the Mann^Whitney test, and
proportions of cases over the two time periods were compared
using the chi-squared test. A P-value of<0.05 was considered
to be statistically signi¢cant.
R E S U L T S
The mean annual incidence of MCD onMerseyside increased
between 1992 (4.0/100 000 per year) and 1997 (7.2/100 000 per
year) and is shown by age breakdown inTable1 (data supplied
by Public Health Laboratory Service (PHLS) Communicable
Disease Surveillance Centre).
The diagnosis of MCD was con¢rmed microbiologically
signi¢cantly more often in the second epoch, although the
proportion of culture-positive isolates was signi¢cantly
reduced. There was no signi¢cant di¡erence between the two
time periods in the proportion of cases referred by their gen-
eral practitioner who had received prehospital intramuscular
penicillin (Table 2).
The proportion of children undergoing lumbar puncture
did decrease signi¢cantly. In the second time period, 29 of 64
(45.3%) were con¢rmed by more than one test, 15 of 64
(23.4%) by PCR alone, four of 64 (6.25%) byAD alone, and
two of 64 (3.1%) by throat swab alone.
There was no di¡erence in gender incidence, but median
age was higher in the second epoch (Table 2).This was due to a
higher proportion of older children and teenagers in the later
epoch, producing a second smaller peak in the teenage years
(Figure 1). The proportion of cases with serogroup C disease
signi¢cantly increased in the second epoch, particularly in
children over 5 years of age.
The case-fatality rate was lower in the second time period
(6/85, 7.1%) than in the ¢rst (13/126,10.3%), but this di¡erence
was not statistically signi¢cant (P 0.42, chi-squared test).
Table 3 shows the complication rates in the two time periods.
The median duration of hospital stay was 6 days (range 1^46
days) in the ¢rst time period, compared to 8 days (range 4^35
days) in the second, but this di¡erence was not statistically
signi¢cant.
D I S C U S S I O N
This study demonstrates improved microbiological con¢rma-
tion of MCD, despite a reduction in culture-positive isolates.
The median age of cases has risen over the 5-year period
between the two epochs, probably as a result of a second smal-
ler peak in the early teenage years (Figure 1). This was
Table 1 Comparison of incidence data (number of new cases per
100 000 population per year) for meningococcal disease in Mersey-
side between 1992 and 1997 by age group. Incidence data are not
available for age groups 10±16 years. Data supplied by PHLS Com-
municable Disease Surveillance Centre
1992 1997
Total incidence 4.0 7.2
< 1 year 99.1 253.1
1±4 years 60.3 89.4
5±9 years 9.9 29.8
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associated with an increase in the proportion of serogroup C
disease.
Newer techniques, such as PCR for detection of meningo-
coccal DNA, are con¢rming a higher proportion of cases.The
introduction of a national service for the diagnosis of menin-
gococcal disease by PCR at the Meningococcal Reference
Unit (MRU) inOctober1996 increased the number of labora-
tory-con¢rmed cases of meningococcal disease by 35% in the
¢rst year [11]. Our clinically based data set fromone area of the
UK shows an increase in laboratory-con¢rmed cases of 23%
with PCR.The sialyltransferase PCR assay is able to discrimi-
nate between serogroups B and C, which together account for
95% of clinical MCD in England andWales. It is used on spe-
cimens reactive in either or both screening tests, but as it is less
sensitive than the screening assays, not all specimens positive
on screening assay can be con¢rmedwith a serogroup [11].
Figure 1 Age distribution of serogroups over two epochs (Sep-
tember 1992 to April 1994, and November 1997 to September
1998). NG, not groupable.
Table 2 Demographics and microbiology over two epochs (September 1992 to April 1994 and November 1997 to September 1998)
1992±94
n (%)
1997±98
n (%) P
Total 126 85
Males 69 (55%) 48 (57%) NS
Median age (years) 1.7 2.49 0.013*
Age range (years) 0.3±14 0.2±15.9
General practitioner referral 69 (55%) 40 (47%) NS
Pre-admission penicillin 22/69 (32%) 13/40 (33%) NS
Con®rmed microbiologically 78 (62%) 64 (75%) 0.04*
Con®rmed on blood/CSF culture alone 67/78 (86%) 13/64 (20%) < 0.0005*
Con®rmed on AD/PCR/throat swab 11/78 (14%) 51/64 (80%) < 0.0005*
Lumbar puncture done 59 (47%) 10 (12%) < 0.0005*
Positive CSF culture 23/59 (39%) 4/10 (40%) NS
Positive blood culture 52 (41%) 28 (33%) NS
Serogroup B 59/78 (76%) 30/64 (47%) < 0.0005*
Serogroup C 14/78 (18%) 30/64 (47%) < 0.0005*
Non-groupable (NG) 5/78 (6%) 4/64 (6%) NS
*P< 0.05.
Table 3 Complication rates over two epochs (September 1992 to
April 1994 and November 1997 to September 1998)
1992±94
n (%)
1997±98
n (%)
Total no. of patients 126 85
Total no. of complications 25 (19.8%) 5 (5.9%)
Skin/digit loss 3 (2.4%) 1 (1.1%)
Limb amputations 0 0
Subdural collection 2 (1.6%) 0
Hemiplegia 1 (0.8%) 0
Severe deafness 1 (0.8%) 0
Seizures on day 1 18 (14.3%) 4 (4.7%)
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The Chief Medical O¤cer's guidelines for the prehospital
management of MCD recommend that children with a sus-
pected diagnosis of MCD should receive intramuscular or
intravenous penicillin from their general practitioner before
admission to hospital. OnMerseyside, the proportion of chil-
dren receiving prehospital parenteral penicillin has remained
unchanged at 32%. This is comparable with Gloucestershire,
where 40% of cases referred by their general practitioner had
received preadmission benzylpenicillin [12]. It should be
acknowledged that not all cases would have been evident as
probableMCDwhen seen by the general practitioner.
Penicillin pretreatment cannot account for the reduction
in culture-positive isolates. Probably the most signi¢cant fac-
tor is the reduced number of lumbar punctures that are being
performed (Table 2). The falling lumbar puncture rate re£ects
a change in clinical management, consequent on consensus
policy that performing lumbar puncture in meningococcal
septicemia may be detrimental in a child su¡ering from cardi-
ovascular instability.
Although a positive throat swab culture does not con¢rm
invasiveMCD, a positive throat swab culture may provide ser-
otype and subtype data which are not available from non-cul-
ture methods such as AD and PCR. In exceptional cases (2/64
in the second epoch), a positive throat swab may be the only
con¢rmation of disease in clinically diagnosedMCD.
Increased microbiological con¢rmation provides additional
serogroup data, which are of value to local Consultants in
Communicable Disease (CCDC) in managing clusters and
outbreaks. These data demonstrate a rising proportion of
group C disease, for which conjugate vaccines have recently
been introduced to theUK [13].
C O N C L U S I O N
On Merseyside, culture isolates in MCD have reduced in
number, mainly due to fewer lumbar punctures being per-
formed. This is o¡set by improved diagnostic yield with the
newer bacteriologic methods, AD and PCR, which can yield
positive results despite penicillin pretreatment. Overall, bac-
teriologic con¢rmation has increased. There has been an
increase in the median age of cases. Serogroup C disease con-
tinues to rise, particularly in teenagers.
We support the recommendations that, in addition to
blood culture, throat swab culture, bacterial AD tests and
PCR should be performed on all children with suspected
MCD, in order to improve the microbiological con¢rmation
rate. PCR is now routinely available as a diagnostic test in
England andWales, and all samples are sent to a meningococ-
cal reference laboratory for analysis. Rapid con¢rmation of
the diagnosis in MCD allows con¢dent management of
patients and contacts, and provides epidemiologic data for
monitoring vaccine e¤cacy.
A CK N O W L ED G ME N T S
We thank the infection control nurses Mrs Julie Hughes and
Mrs Doreen Brown and the technical sta¡ of the Microbiol-
ogy Department, RLCH NHS Trust, Alder Hey for their
contribution to the study, and the PHLS Meningococcal
ReferenceUnit inManchester for the PCR results.
R E F E R E N C E S
1. Cartwright K, Reilly S,White D, Stuart J. Early treatment with
parenteral penicillin in meningococcal disease. BrMedJ1992; 305:
143^7.
2. Nadel S, Levin M, Habibi P.Treatment of meningococcal disease
in childhood. In: Cartwright K, ed. Meningococcal disease. John
Wiley & Sons,1995: 207^43.
3. Bohr V, Rasmussen N, Hansen B et al. 875 cases of bacterial
meningitis: diagnostic procedures and the impact of pre-admis-
sion antibiotic therapy. Part III of a three part series. J Infect1983; 7:
193^202.
4. van Deuren M, van Dijke BJ, Koopman RJJ et al.Rapid diagnosis
of acute meningococcal infections by needle aspiration or biopsy
of skin lesions. BrMedJ1993; 306: 1229^32.
5. Kaczmarski EB. Meningococcal disease in England and Wales:
1995.CommunDisRev1995; 7: R55^9.
6. Cartwright K, Kroll S. Optimising the investigation of meningo-
coccal disease. BrMedJ1997; 315: 757^8.
7. CDSC. Enhanced surveillance of meningococcal disease.Commun
DisRepWeekly1998; 8(1): 1.
8. Stuart JM, Monk PN, Lewis DA, Constantine C, Kaczmarski
EB, Cartwright Kav. Management of clusters of meningococcal
disease.CommunDisRev1997; 7: R3^5.
9. Riordan FAI, Thomson APJ, Sills JA, Hart CA.Who spots the
spots? Diagnosis and treatment of early meningococcal disease in
children. BrMedJ1996; 313: 1255^6.
10. Newcombe J, Cartwright K, PalmerWH, McFadden J. Polymer-
ase chain reaction of peripheral blood for the diagnosis of menin-
gococcal disease. JClinMicrobiol1996; 34: 1637^40.
11. Kaczmarski EB, Ragunathan PL, Marsh J, Gray SJ, Guiver M.
Creating a national service for the diagnosis of meningococcal dis-
ease by polymerase chain reaction. CommunDis Public Health 1998;
1: 54^6.
12. Wylie PAL, Stevens D, DrakeW, Stuart J, Cartwright K. Epide-
miology and clinical management of meningococcal disease in
west Gloucestershire: retrospective, population based study. Br
MedJ1997; 315: 774^9.
13. CDSC.Vaccination programme for groupCmeningococcal infec-
tion is launched.CommunDisRepWeekly1999; 9(30): 264.
262 Clinical Microbiology and Infection, Volume 6 Number 5, May 2000
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 259±262
